Core Compounds
| Compound | Principal Target | Partner | Indication | Stage of Development |
|---|---|---|---|---|
XL184 |
MET
|
Unpartnered |
MTC |
Phase 3
|
| Recurrent GBM |
Phase 2
|
|||
| RDT in NSCLC; SCLC; HCC; Melanoma, Breast, Ovarian, Gastric/GEJ, Pancreatic, and Prostate Cancers |
Phase 2
|
|||
| NSCLC + erlotinib |
Phase 1b/2
|
|||
| GBM + TMZ + XRT |
Phase 1
|
|||
| Solid Tumors |
Phase 1
|
|||
XL1471 |
PI3K |
Sanofi-Aventis | Endometrial Cancer |
Phase 2
|
| Breast Cancer + trastuzumab +/- paclitaxel |
Phase 1b/2
|
|||
| NSCLC + erlotinib |
Phase 1b/2
|
|||
| Solid Tumors + paclitaxel/carboplatin |
Phase 1b/2
|
|||
| Solid Tumors |
Phase 1
|
|||
XL7651 |
PI3K
|
Sanofi-Aventis | GBM + temozolomide |
Phase 1b/2
|
| NSCLC + erlotinib |
Phase 1b/2
|
|||
| Soid Tumors |
Phase 1
|
|||
XL413 |
Cdc7 |
Unpartnered | Solid Tumors |
Phase 1
|
| Hematologic Malignancies |
Phase 1
|
|||
XL888 |
HSP90 |
Unpartnered | Cancer |
Phase 1
|
- Out-licensed to Sanofi-Aventis. Exelixis currently conducts the majority of clinical development but is reimbursed for 100% of its costs and is eligible to receive milestones and royalties on future product sales.